^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT exon 11 mutation + KIT exon 17 mutation

    i
    Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. (PubMed, Biomedicines)
    The present preclinical study evaluated the potential use of the fibroblast growth factor receptor inhibitors infigratinib and dovitinib alone or in combination with the mitogen-activated protein kinase inhibitor binimetinib in mouse models of GIST with different sensitivity or resistance to imatinib. In a model with KIT exon 11 and 17 mutations, dovitinib induced tumor necrosis, most likely due to anti-angiogenic effects. Additive effects combining dovitinib with binimetinib were limited.
    Preclinical • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    KIT exon 11 mutation • KIT exon 9 mutation • KIT exon 17 mutation • KIT exon 11 mutation + KIT exon 17 mutation
    |
    imatinib • Mektovi (binimetinib) • Truseltiq (infigratinib) • dovitinib (TKI258)